Advertisement

Search Results

Advertisement



Your search for The ASCO matches 21099 pages

Showing 11451 - 11500


hematologic malignancies
lymphoma

Solid Organ Transplantation and Lymphoma

Survival of patients with Hodgkin and non-Hodgkin lymphomas is increasing, and with that comes the need, in some cases, for solid organ transplantation, often because of treatment-related toxicity. The factors involved in organ transplant among lymphoma survivors were discussed by Philip J....

gynecologic cancers

SGO 2018: Participation in Clinical Trials May Overcome Health Disparities in Ovarian Cancer

Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a study presented at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting on Women’s Cancer (Abstract 6). The study evaluated the effect of ...

lung cancer
immunotherapy

IMpower150: Increased OS With Atezolizumab/Bevacizumab Plus Chemotherapy in Advanced Nonsquamous NSCLC

The phase III IMpower150 study met its coprimary endpoint of overall survival (OS) at interim analysis and showed that first-line treatment with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) plus carboplatin and paclitaxel (chemotherapy) helped patients with advanced...

breast cancer

EBCC-11: Women Report Fewer Side Effects With Partial or Reduced Breast Radiotherapy vs Standard WBRT

The average number of moderate or marked side effects reported by patients with breast cancer is lower if they are treated with radiotherapy to part of the breast or a reduced dose to the whole breast, rather than with standard whole breast radiotherapy (WBRT), according to new findings presented...

pancreatic cancer

First Interim Analysis of Phase III SEQUOIA Trial in Pancreatic Cancer

ARMO BioSciences, Inc, recently announced the completion of the first interim analysis in its phase III SEQUOIA trial in patients with pancreatic cancer. The Data Monitoring Committee (DMC) for SEQUOIA, a clinical trial studying pegilodecakin (AM0010) plus FOLFOX (leucovorin,...

breast cancer

EBCC-11: MINDACT Trial: Patients With Early Breast Cancer and Risk of Locoregional Recurrence

Women with small, low-grade, well-defined breast tumors and a genetic profile that shows they are at low risk of the cancer metastasizing have only a 1.4% risk of locoregional recurrence within 5 years, according to new results from a large randomized trial of nearly 7,000 patients. This low risk...

skin cancer

AAD Issues Guidelines for Treatment of Nonmelanoma Skin Cancer

Skin cancer is the most common cancer in the United States, and nonmelanoma skin cancer is the most common type of skin cancer, affecting more than 3 million Americans every year. Moreover, nonmelanoma skin cancer incidence is growing at an exponential rate—between 1976–1984 and...

gynecologic cancers
immunotherapy

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers...

breast cancer

EBCC-11: Sentinel Lymph Node Biopsy in Triple-Negative and HER2-Positive Breast Cancers

Sentinel lymph node biopsies may be safely avoided for some women, according to research presented at the 11th European Breast Cancer Conference (EBCC-11). Two new studies show that women with either triple-negative or HER2-positive types of breast cancer, whose cancers respond well to chemotherapy ...

colorectal cancer
immunotherapy

FDA Accepts sBLA for Nivolumab Plus Ipilimumab in Previously Treated MSI-H or dMMR Metastatic Colorectal Cancer

On March 27, the U.S. Food and Drug Administration (FDA) accepted a supplemental biologics license application (sBLA) for nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the treatment of adults with microsatellite instability–high (MSI-H) or mismatch repair deficient...

leukemia
immunotherapy

FDA Expands Approval of Blinatumomab for Certain Patients With B-Cell Precursor ALL

The U.S. Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). In patients who have achieved remission after...

Linda D. Bosserman, MD, FACP, FASCO, Named Editor-in-Chief of Journal of Oncology Practice

Linda D. Bosserman, MD, FACP, FASCO, has been named Editor-in-Chief of the Journal of Oncology Practice (JOP), an ASCO publication. Dr. Bosserman is a recognized leader in cancer care delivery with a deep understanding of the issues impacting all types of oncology practices. "We are delighted ...

solid tumors

SSO 2018: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Frozen section evaluation of sentinel lymph nodes after neoadjuvant chemotherapy has a higher false-negative rate than in the primary surgical setting, particularly for small tumor deposits. However, it is unknown whether similar false positive rates occur after chemotherapy. Researchers led by...

gynecologic cancers

SGO 2018: New Data Suggest Cervical Cancer Age-Based Screening Guidelines Should Be Reconsidered

One in five women diagnosed with cervical cancer in the United States will be diagnosed after the age of 65, suggesting that the recommended age to stop cervical cancer screening should be reconsidered, according to research presented at the Society of Gynecologic Oncology’s (SGO) 2018 Annual ...

breast cancer

EBCC-11: Double Mastectomy in BRCA1 and BRCA2 Carriers

Healthy women who carry a breast cancer–causing mutation in the BRCA1 gene not only reduce their risk of developing the disease but also their chances of dying from it if they have both breasts removed, according to new research presented at the 11th European Breast Cancer Conference...

bladder cancer

FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

On March 26, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors. Breakthrough Therapy ...

gynecologic cancers

SGO 2018: Gender Differences May Play a Role in Lack of HPV Vaccination

Parents are less likely to vaccinate adolescent boys than girls with the human papillomavirus (HPV) vaccine, and they are twice as likely to report their main reason as a lack of provider recommendation, according to a study presented at the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting ...

gastrointestinal cancer

SSO 2018: Improved Survival With Nodal Downstaging in Gastric Cancer if ypN0 Is Achieved

A team of researchers led by Naruihiko Ikoma, MD, MS, of The University of Texas MD Anderson Cancer Center in Houston, analyzed outcomes in 316 patients with gastric cancer to determine whether patients who had clinically positive nodal disease before preoperative therapy have...

hepatobiliary cancer

Lenvatinib Mesylate Approved in Japan for Unresectable HCC

On March 23, the multiple-receptor tyrosine kinase inhibitor lenvatinib mesylate (Lenvima) was approved in Japan for unresectable hepatocellular carcinoma (HCC). This is the first approval worldwide of lenvatinib mesylate for the indication of unresectable HCC and the first new systemic therapy to...

breast cancer

EBCC-11: DCIS Less Likely to Recur in Patients Who Are Postmenopausal, ER-Positive

Patients with ductal carcinoma in situ (DCIS) are less likely to have recurrent disease if they are postmenopausal or if their tumor is estrogen receptor (ER)-positive, according to research presented at the 11th European Breast Cancer Conference (EBCC-11) (Abstract 215). DCIS accounts for about...

skin cancer
immunotherapy

SSO 2018: Outcomes of Patients With Metastatic Melanoma Selected for Surgery After Immunotherapy

Immunotherapy has transformed the treatment of metastatic melanoma, with 3-year survival rates surpassing 50% for appropriate patients. However, many of these patients still require surgery, but very little research has been done on this group of patients to determine whether surgery after...

gynecologic cancers

SGO 2018: PARP-7 Protein May Play a Significant Role in Survival for Ovarian Cancer

Patients with ovarian cancer with genetic amplification in the PARP-7 protein survived longer than those without the mutation, according to a presentation at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting on Women’s Cancer. These results call for researchers to further...

lung cancer
immunotherapy

IMpower131 Study: Atezolizumab Plus Chemotherapy in Advanced Squamous NSCLC

On March 20, Genentech announced that the phase III IMpower131 study met its coprimary endpoint of progression-free survival (PFS) and demonstrated that the combination of atezolizumab (Tecentriq) plus chemotherapy (carboplatin and nanopartical albumin-bound [nab]-paclitaxel [Abraxane])...

breast cancer

EBCC-11: Risk of a Second Breast Cancer Can Be Better Quantified in Patients With a BRCA Mutation

The risk of a second breast cancer in patients with high-risk BRCA gene mutations can be more precisely predicted by testing for several other genetic variants, each of which are known to have a small impact on breast cancer risk, according to new research presented at the 11th European Breast...

leukemia
immunotherapy

Bijal D. Shah, MD, on What ALL Tells Us About CAR T Cells

Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses key studies of CAR T-cell therapy in relapsed B-cell ALL and the adverse events that this treatment may cause.

hepatobiliary cancer

Anne M. Covey, MD, on HCC: Screening and Diagnosis Updates

Anne M. Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest recommendations for screening and diagnosing hepatocellular carcinoma, an aggressive tumor marked by increasing incidence in the United States and a poor 5-year survival rate.

breast cancer

Anthony D. Elias, MD, on Triple-Negative Breast Cancer: Treatment Update

Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications of newly approved olaparib for gBRCA-mutant breast cancer.

breast cancer

William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Treatment Update

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses recent evidence on the efficacy, safety, and utility of HER2-targeted treatments in the adjuvant setting for early-stage and advanced breast cancers.

issues in oncology

Lee N. Newcomer, MD, on Managed Care in America: Expert Perspective

Lee N. Newcomer, MD, who recently retired as Senior Vice President for Oncology and Genetics at UnitedHealth Group, discusses lessons learned during his long career in managed care, where we are, and where we need to go.

cns cancers

We Need to Fill the Gap Between Pediatric and Adult Oncology Care

When I was 15, and just 6 weeks into my sophomore year in high school, I heard a loud sound similar to a gunshot in my head and minutes later I was engulfed in a grand mal seizure, now called tonic-clonic seizure, and rushed to the hospital. A magnetic resonance imaging (MRI) scan found a small...

Baylor Receives $3 Million to Fund Grants in Tobacco Control, Cancer Screening, and Cancer Treatments

RESEARCHERS AT Baylor College of Medicine have received more than $3 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund three new grants focused on tobacco control, cancer screening, and novel treatments for cancer in children and adults.  CPRIT was launched in 2009...

breast cancer

When Is Active Surveillance Appropriate in the Treatment of DCIS?

In 2017, more than 63,000 women in the United States were diagnosed with in situ breast cancer. The overwhelming majority of those women, about 83%, were diagnosed with ductal carcinoma in situ (DCIS), a condition characterized by the presence of abnormal cells confined to the breast milk ducts;...

skin cancer

April K.S. Salama, MD, on Melanoma: Treating Recurrent or Progressive Distant Disease

April K.S. Salama, MD, of Duke Cancer Institute, talks about how to select systemic therapy for a patient with previously treated metastatic melanoma.

colorectal cancer

Duration of Adjuvant Oxaliplatin-Based Therapy for Stage III Colon Cancer

“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of the Bronx, New York. When he is not in his clinic, he can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. The opinions...

CancerCare Publishes New White Paper on the Provider Perspective in Treatment Decision-Making

CANCERCARE has announced the publication of a new white paper highlighting perspectives from oncology providers on the importance and utility of including patient priorities in treatment decisions. “Decision Making at the Point of Care: Voices of Oncology Providers” was developed as part of...

issues in oncology

Raising Awareness of the Link Between Alcohol and Cancer

Prevention in Oncology is guest edited by Jennifer Ligibel, MD, Chair of ASCO’s Energy Balance Working Group and a member of ASCO’s Cancer Survivorship and Cancer Prevention Committees. Dr. Ligibel is Director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber Cancer...

breast cancer

Breast Cancer Care in U.S. Territories Seems to Lag Behind Care in Continental United States

OLDER WOMEN residing in U.S. territories are less likely to receive recommended or timely care for breast cancer compared with similar women residing in the continental United States, according to Yale researchers, whose findings were published in Health Affairs.1  “Inferior breast cancer care in...

multiple myeloma

EXPERT POINT OF VIEW: Kenneth C. Anderson, MD, and S. Vincent Rajkumar, MD

AT A PREMEETING webinar, American Society of Hematology then President Kenneth C. Anderson, MD, Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute, Boston, commented: “This study demonstrates this new treatment has good...

prostate cancer

James L. Mohler, MD, on Prostate Cancer: Management Approaches

James L. Mohler, MD, of Roswell Park Cancer Institute, discusses personalized medicine, molecular risk stratification, and better androgen-deprivation therapy for men with prostate cancer.

colorectal cancer
immunotherapy

Alan P. Venook, MD, on Selecting Treatment for Advanced Colorectal Cancer

Alan P. Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses which biomarkers to order and when, the role of checkpoint inhibitors, and chemotherapy choices.

pancreatic cancer

Gut Bacteria May Determine Speed of Tumor Growth in Pancreatic Cancer

The population of bacteria in the pancreas increases more than a thousandfold in patients with pancreatic cancer and becomes dominated by species that prevent the immune system from attacking tumor cells. These are the findings of an early study conducted on pancreatic ductal adenocarcinoma,...

lymphoma

FDA Updates Public Information About Known Risk of Lymphoma From Breast Implants

On March 21, the U.S. Food and Drug Administration (FDA) issued updated information about its understanding of breast implant–associated anaplastic large cell lymphoma (ALCL). The agency is providing an updated number of medical device reports (ie, adverse event reports) and medical...

leukemia

FDA Expands Nilotinib Indication to Pediatric Patients With CML

Today, the U.S. Food and Drug Administration (FDA) expanded the indication for nilotinib (Tasigna) to include treatment of first- and second-line pediatric patients 1 year of age or older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase. In the United...

leukemia

Ellin Berman, MD, on CML: Disease Management During Pregnancy

Ellin Berman, MD, of Memorial Sloan Kettering Cancer Center, discusses the effects of TKI therapy on fetal development, its impact on pregnancy outcomes, and how to develop an effective treatment plan.

prostate cancer

EAU 2018: Prostate MRI Reveals More Clinically Significant Cancers, Reduces Overdiagnosis Compared to Standard Biopsy

A large international study has shown that magnetic resonance imaging (MRI) can reduce the number of invasive prostate biopsies by up to 28%. The PRECISION trial showed that using MRI to target prostate biopsies leads to more harmful and fewer harmless prostate cancers being diagnosed. The results...

solid tumors

EAU 2018: Study Finds a Quarter of Penile Cancer Patients Do Not Receive Recommended Treatment

A major international survey has found that around a quarter of patients with penile cancer are not receiving the recommended treatment, and that these patients had half the survival rate of those who were treated according to guidelines. The study, presented at the European Association of Urology...

kidney cancer
prostate cancer
bladder cancer

EAU 2018: Survey Shows Greater Suicide Rate in Patients With Urologic Cancers

A major UK survey has shown that patients with urologic cancer—such as prostate, bladder, or kidney cancer—are five times more likely to commit suicide than people without cancer. The analysis also shows that patients with cancer generally are around three times more likely to commit...

prostate cancer

FDA Grants Priority Review to sNDA for Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

On March 19, a supplemental New Drug Application (sNDA) for enzalutamide (Xtandi) was accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). If approved, the sNDA would expand the indication of enzalutamide to include men with nonmetastatic...

lymphoma
immunotherapy

FDA Expands Approval of Brentuximab Vedotin for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination With Chemotherapy

On March 20, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy. “Today’s approval represents an improvement in the initial...

solid tumors
colorectal cancer
supportive care
pain management
palliative care
survivorship
issues in oncology

Support, Inform Patients With ASCO Resources

Stock your practice with ASCO resources for your patients. Visit ASCO’s patient information website, Cancer.Net, for a newly updated comprehensive guide to colorectal cancer at cancer.net/colorectal and a shorter, one-page colorectal cancer fact sheet. Copies can be purchased from the ASCO...

Advertisement

Advertisement




Advertisement